Long-term clinical outcomes in type 1 Gaucher disease following 10 years of imiglucerase treatment

OBJECTIVE: We studied the effect of long-term alglucerase/imiglucerase (Ceredase®/Cerezyme®, Genzyme, a Sanofi company, Cambridge, MA, USA) treatment on hematological, visceral, and bone manifestations of Gaucher disease type 1 (GD1). METHODS: The International Collaborative Gaucher Group (ICGG) Gau...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Weinreb, Neal J., Goldblatt, Jack, Villalobos, Jacobo, Charrow, Joel, Cole, J. Alexander, Kerstenetzky, Marcelo, vom Dahl, Stephan, Hollak, Carla
Format: Artigo
Idioma:Inglês
Publicat: Springer Netherlands 2012
Matèries:
Original Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3648688/
https://ncbi.nlm.nih.gov/pubmed/22976765
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10545-012-9528-4
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars